Pipeline

Athos Therapeutics is a clinical stage company with assets in Inflammatory Bowel Diseases, lupus, and cancer. Athos is also pursuing discovery efforts against a range of validated and novel drug targets for patients with different autoimmune diseases.

Disease Application

Small Molecule

Discovery

Preclinical

Phase 1

Phase 2

Lead Programs

IBD, SLE, T1D

ATH-063

AD, IBD, Scleroderma

ATH-391

AML

ATH-272

Early Stage Programs

Autoimmune

ATH-091

IBD, Sjogren’s Syndrome

ATH-131

Fibrosis

ATH-301

Autoimmune

ATH-501

AD, IBD, EoE

ATH-601

IBD: Inflammatory Bowel Diseases

SLE: Systemic Lupus Erythematosus

CD: Celiac Disease

AD: Atopic Dermatitis

RA: Rheumatoid Arthritis

AML: Acute Myeloid Leukemia